LWAYMEDIUM SIGNALOPERATIONAL10-K

Lifeway Foods shows strong operational momentum with 53.6% net income growth and significantly expanded capital investments, though burning through cash reserves in the process.

The company is executing a major growth phase with capital expenditures jumping over 300% to $27.4M, indicating substantial facility expansion or equipment upgrades. This aggressive investment strategy has delivered impressive results with net income growth outpacing revenue growth, suggesting improving operational efficiency and margin expansion.

Comparing 2026-03-17 vs 2025-03-14View on EDGAR →
FINANCIAL ANALYSIS

Lifeway demonstrates robust operational performance with net income surging 53.6% to $13.9M while gross profit expanded 19.8% to $58.2M, indicating strong demand for their probiotic products and improving margins. The company is investing heavily in growth with capital expenditures jumping 308.6% to $27.4M, funded by drawing down cash reserves (declining 66.7% to $5.6M) while maintaining a strong balance sheet with stockholders' equity growing 19.3% to $85.8M. The increased inventory levels (+37%) and manufacturing capacity investments position the company for continued expansion, though cash management will need monitoring given the significant drawdown.

FINANCIAL STATEMENT CHANGES
Capital Expenditure
Cash Flow
+308.6%
$6.7M→$27.4M

Capital expenditure jumped 308.6% — major investment cycle underway; assess returns on deployment.

Cash & Equivalents
Balance Sheet
-66.7%
$16.7M→$5.6M

Cash declined 66.7% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Net Income
P&L
+53.6%
$9.0M→$13.9M

Net income grew 53.6% — bottom-line growth signals improving overall business health.

Interest Expense
P&L
+43.8%
$267K→$384K

Interest expense surged 43.8% — significant debt increase or rising rates materially impacting earnings.

Inventory
Balance Sheet
+37%
$8.7M→$11.9M

Inventory surged 37% — growing faster than typical sales pace; potential demand softening or supply chain overcorrection.

Total Debt
Balance Sheet
-26.7%
$3.8M→$2.8M

Debt reduced 26.7% — deleveraging strengthens balance sheet and reduces financial risk.

Gross Profit
P&L
+19.8%
$48.6M→$58.2M

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Stockholders Equity
Balance Sheet
+19.3%
$71.9M→$85.8M

Equity base grew 19.3% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Operating Income
P&L
+16.7%
$13.9M→$16.2M

Operating income improving — cost discipline or growing revenue base absorbing fixed costs.

Total Assets
Balance Sheet
+16.6%
$90.5M→$105.6M

Asset base grew 16.6% — expansion through organic growth, acquisitions, or capital deployment.

LANGUAGE CHANGES
NEW — 2026-03-17
PRIOR — 2025-03-14
ADDED
As of March 2, 2026, 15,149,600 shares of the registrant s common stock, no par value, were outstanding.
Management s Discussion and Analysis of Financial Condition and Results of Operations 1 9 Item 7A.
Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 29 Item 9A.
Unless otherwise noted herein, all amounts in this Form 10-K are in thousands, except per share numbers.
Net sales of products by category were as follows for the years ended December 31: 2025 2024 In thousands $ % $ % Drinkable Kefir other than ProBugs $ 181,423 85% $ 153,493 82% Cheese 16,571 8% 14,554 8% Cream and other 8,693 4% 8,299 4% Drinkable Yogurt 2,284 1% 5,619 3% Probugs Kefir 2,214 1% 3,421 2% Other dairy 1,311 1% 1,434 1% Net Sales $ 212,496 100% $ 186,820 100% 1 Product innovation and new product development Lifeway is committed to maintaining its position as the leading producer of kefir and a recognized leader in the market for probiotic products.
+7 more — sign up free →
REMOVED
As of March 14, 2025, 15,203,241 shares of the registrant s common stock, no par value, were outstanding.
Management s Discussion and Analysis of Financial Condition and Results of Operations 20 Item 7A.
Changes in and Disagreements With Accountants on Accounting and Financial Disclosure 2 8 Item 9A.
Thanks to our exclusive blend of kefir cultures, each cup of our flagship low fat kefir contains 12 live and active cultures and 25 to 30 billion beneficial CFU (Colony Forming Units) at the time of manufacture.
Net sales of products by category were as follows for the years ended December 31: 2024 2023 In thousands $ % $ % Drinkable Kefir other than ProBugs $ 153,493 82% $ 127,726 80% Cheese 14,554 8% 13,781 9% Cream and other 8,299 4% 7,382 4% Drinkable Yogurt 5,619 3% 6,236 4% Probugs Kefir 3,421 2% 3,429 2% Other dairy 1,434 1% 1,569 1% Net Sales $ 186,820 100% $ 160,123 100% 1 Product innovation and new product development Lifeway is committed to maintaining its positions as the leading producer of kefir and a recognized leader in the market for probiotic products.
+7 more — sign up free →
MORE OPERATIONAL SIGNALS
HOFTHIGHHOFT completed a major divestiture of its Pulaski and Samuel Lawrence furniture ...
2026-04-17
CTRNHIGHCTRN underwent a dramatic operational turnaround with a complete repositioning f...
2026-04-15
ORBSHIGHORBS has undergone a complete business transformation from packaging and e-comme...
2026-04-15
BRFHHIGHBRFH completed a transformative acquisition of Arps Dairy in October 2025, drama...
2026-04-15
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →